Combining variant detection and fragment length analysis improves detection of minimal residual disease in postsurgery circulating tumour DNA of stage II–IIIA NSCLC patients

Stage II–IIIA nonsmall cell lung cancer (NSCLC) patients receive adjuvant chemotherapy after surgery as standard‐of‐care treatment, even though only approximately 5.8% of patients will benefit. Identifying patients with minimal residual disease (MRD) after surgery using tissue‐informed testing of po...

Descripción completa

Detalles Bibliográficos
Autores principales: Vessies, Daan C. L., Schuurbiers, Milou M. F., van der Noort, Vincent, Schouten, Irene, Linders, Theodora C., Lanfermeijer, Mirthe, Ramkisoensing, Kalpana L., Hartemink, Koen J., Monkhorst, Kim, van den Heuvel, Michel M., van den Broek, Daan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9297781/
https://www.ncbi.nlm.nih.gov/pubmed/35674097
http://dx.doi.org/10.1002/1878-0261.13267

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9297781/
https://www.ncbi.nlm.nih.gov/pubmed/35674097
http://dx.doi.org/10.1002/1878-0261.13267

Ejemplares similares